| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | IL-22 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6408H9873N1706O2016S44 |
| Molar mass | 144479.04 g·mol−1 |
 N Y (what is this?) (verify) | |
Fezakinumab is a human monoclonal antibody againstinterleukin-22,[1] designed for the treatment ofpsoriasis andrheumatoid arthritis.[2]
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired byPfizer. Fezakinumab, in combination withmethotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in theScoring Atopic Dermatitis (SCORAD) score for patients with severeatopic dermatitis.[4]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
